OnKure Therapeutics, Inc., formerly Reneo Pharmaceuticals, Inc., is a clinical-stage biopharmaceutical company focused on the discovery and development of precision medicines that target biologically validated drivers of cancers that are underserved by available therapies. Using a structure-based drug design platform, the Co. is building a robust pipeline of tumor-agnostic candidates. Co. is developing OKI-219, a selective PI3K?H1047R inhibitor, as its lead program. OKI-219 is being evaluated in a Phase I clinical trial in solid tumor patients with PI3K?H1047R mutations, including breast cancer. The OKUR average annual return since 2021 is shown above.
The Average Annual Return on the OKUR average annual return since 2021 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether OKUR average annual return since 2021 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the OKUR average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|